EUVIMEDObjevte EUVIMED
Crossref

Lurasidone: new development for the treatment of psychosis

Paul Stokes, Allan Young

Future Prescriber · 2013

DOI: 10.1002/fps.106 ↗

At a glance

Journal article in Future Prescriber, 2013. Written by Paul Stokes and 1 co-authors.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Although we have had efficacious medications for both schizophrenia and bipolar disorder for over half a century, there remains a clear need for more effective and better‐tolerated treatments for both conditions. Current antipsychotics often have troubling side‐effect profiles particularly with respect to weight gain and cardiometabolic parameters. These drawbacks also extend to treatment of mania and there are very few evidence‐based treatments for the depressed phases of bipolar disorder. The introduction of a novel treatment with a potentially better risk‐to‐benefit profile is therefore welcome.

Cite

APA

Stokes, P., & Young, A. (2013). Lurasidone: new development for the treatment of psychosis. Future Prescriber. https://doi.org/10.1002/fps.106

Vancouver

Stokes P, Young A. Lurasidone: new development for the treatment of psychosis. Future Prescriber. 2013. doi:10.1002/fps.106

BibTeX
@article{Stokes2013,
  author = {Stokes, Paul and Young, Allan},
  title = {Lurasidone: new development for the treatment of psychosis},
  journal = {Future Prescriber},
  year = {2013},
  doi = {10.1002/fps.106}
}
Start for free →